A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback